Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Keryx Biopharmaceuticals    KERX

KERYX BIOPHARMACEUTICALS (KERX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Keryx Biopharmaceuticals : Traders Favorite: Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 08:05pm CEST

NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings.

Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 5.48% to $8.47. The company, on March 11, announced its results for the fourth quarter and year ended December 31, 2012. The net loss for the 4th quarter ended December 31, 2012 was $6.6 million, or $0.09 per share versus $8.4 million for quarter 2011, representing a decrease of $1.8 million and Net loss for the year ended December 31, 2012, was $22.7 million versus $28.1 million for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.

At December 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $14.7 million, as compared to $39.5 million at December 31, 2011.

Has KERX Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=KERX (OR Just copy and paste the link)

McDonald's Corporation(NYSE:MCD) shares decreased 1.13% to $98.80. The company, on April 19, posted first-quarter profit that was little changed as same-store sales dropped in the U.S. for the first time since 2003 amid soft global demand. Net income was about $1.27 billion, or $1.26 share, compared with $1.27 billion, or $1.23, a year earlier. Analysts projected $1.26, the average of 29 estimates compiled by analyst.

Has MCD Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MCD (OR Just copy and paste the link)

Additionally, MCD?s stock had its ?buy? rating restated by analysts at Janney Montgomery Scott in a research report issued to clients and investors on April 16. They currently have a $115.00 price target on the stock.

Merck & Co., Inc.(NYSE:MRK) shares fell 0.38% to $47.31. The company, on April 1st reported that it will hold its first-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Wednesday, May 1.

Has MRK Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MRK (OR Just copy and paste the link)

Additionally, the company, on April 10, announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA).

Hertz Global Holdings, Inc. (NYSE:HTZ) shares decreased 0.76% to $23.54. The company, on April 16, agreed to acquire a 20% stake in Beijing-based China Auto Rental Holdings Inc. to expand its presence in China's car-rental market. Financial terms weren't disclosed.

How Should Investors Trade HTZ Now? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=HTZ (OR Just copy and paste the link)

Additionally, the company, on April 8, announced that its wholly-owned subsidiary, The Hertz Corporation ("Hertz"), has successfully completed a repricing of its currently outstanding $1,372 billion senior secured tranche B term loan facility. As part of the repricing, the tranche B term loans will be replaced by new tranche B-2 term loans.

About bestdarnpennystocks.com
bestdarnpennystocks.com?s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:
bestdarnpennystocks.com
1419 Westwood Blvd Los Angeles, CA
90024-4911
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KERYX BIOPHARMACEUTICALS
06/21KERYX BIOPHARMACEUTICALS : Announces Participation in a Renal Disease Panel at t..
AQ
06/20Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at ..
GL
06/15KERYX BIOPHARMACEUTICALS INC : Change in Directors or Principal Officers, Financ..
AQ
05/30KERYX BIOPHARMACEUTICALS : Wired News – Keryx Biopharmaceuticals Shares Results ..
AC
05/30KERYX BIOPHARMACEUTICALS : Pharmaceuticals Announces Upcoming Investor Presentat..
AQ
05/30Keryx Pharmaceuticals Announces Upcoming Investor Presentations
GL
05/28KERYX BIOPHARMACEUTICALS : Announces Data from an Investigator Sponsored Trial o..
AQ
05/26KERYX BIOPHARMACEUTICALS : Announces Data from an Investigator Sponsored Trial o..
AQ
05/25KERYX BIOPHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements an..
AQ
05/25Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial ..
GL
More news
News from SeekingAlpha
06/19Tricida Prepares For $175 Million U.S. IPO 
06/06ONCE THE TRIAL IS OVER : A Look At Synergy 
06/05Tricida readies IPO 
05/29Keryx Biopharmaceuticals (KERX) On Randomized Trial Of Ferric Citrate In Adva.. 
05/28YOUR DAILY PHARMA SCOOP : Keryx, Reata And AstraZeneca Report Positive Results 
Financials ($)
Sales 2018 105 M
EBIT 2018 -75,0 M
Net income 2018 -72,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 5,79x
Capi. / Sales 2019 3,50x
Capitalization 606 M
Chart KERYX BIOPHARMACEUTICALS
Duration : Period :
Keryx Biopharmaceuticals Technical Analysis Chart | KERX | US4925151015 | 4-Traders
Technical analysis trends KERYX BIOPHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 6,79 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Jodie P. Morrison Chief Executive Officer & Director
Michael W. Rogers Chairman
Christine A. Carberry Chief Operating Officer & Senior Vice President
Scott A. Holmes CFO, Principal Accounting Officer & Senior VP
John F. Neylan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
KERYX BIOPHARMACEUTICALS11.61%606
GILEAD SCIENCES-0.98%92 917
VERTEX PHARMACEUTICALS3.10%40 169
REGENERON PHARMACEUTICALS-10.38%35 698
SAREPTA THERAPEUTICS INC176.22%10 071
GENMAB-3.97%9 722